Clinical Trial Update: Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC [Phase 2]

View source ↗

Summary

This entry notes a Phase 2 neoadjuvant immunotherapy trial for localized non-small cell lung cancer with an EGFR activating mutation, currently active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Non-small Cell Lung Cancer, EGFR Activating Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING